As compared with the less studied ACTR3, the potential of ARPC5 as a prognostic biomarker has been investigated in multiple cancer types such as hepatocellular carcinoma (Huang et al., 2021) and multiple myeloma (Xiong and Luo, 2018). This evidence concerns the gene ACTR3 and plasma cell myeloma.